Harrow announced the launch of Harrow Access for All (HAFA), a patient access program designed to simplify and reduce the cost of obtaining the company's ophthalmic medications, the company said in a press release. 

According to Harrow, HAFA builds on the success of the Vevye Access for All (VAFA) initiative, which launched in March 2025. VAFA was designed to improve access and affordability to Vevye (cyclosporine ophthalmic solution) 0.1%, a prescription medication indicated for the treatment of the signs and symptoms of dry eye disease. HAFA now expands this proprietary patient access model from a single product to encompass Harrow’s comprehensive ophthalmic portfolio of branded, authorized generics (AGx) and compounded ophthalmic medications. Beginning in late 2025 and expanding into 2027, the company said HAFA will provide a single, unified access point for prescribers and patients, offering affordability, streamlined prescribing, and predictable access. Eligible commercially insured patients may pay as little as $0, with out-of-pocket costs for all eligible patients capped at $59, ensuring treatment affordability regardless of coverage status, the company said.

The HAFA program will be implemented in 3 phases:

• Phase 1 (Q4 2025 launch expected): Covers the majority of Harrow’s specialty product portfolio, including the upcoming launch of Byqlovi (clobetasol propionate ophthalmic suspension) 0.05%. Eligible patients will pay as little as $0 and no more than $59 out-of-pocket, significantly improving affordability while driving early adoption.

• Phase 2 (first half of 2026 launch expected): Covers the majority of Harrow’s specialty product portfolio, and will include an expanded portfolio of AGx offerings, ensuring continued and improved patient access.

• Phase 3 (2027 launch expected): HAFA will ultimately extend across Harrow’s full portfolio of specialty, AGx, and compounded medicines. For eligible patients not covered by insurance, the program ensures uninterrupted access by offering an AGx or affordable cash-pay options, depending on the product, with compounded medication alternatives available as appropriate for the individual patients—guaranteeing that every patient can receive the medication they need.

HAFA will incorporate a centralized HarrowAccess.com portal designed to streamline the prescribing process and create a more efficient experience for both physicians and patients. The portal provides access to Harrow’s portfolio of specialty, generic, and compounded ophthalmic medications, as well as Harrow-affiliated partner products. Prescribers can use the platform to create protocol decision trees tailored to their practice, ensuring that patients receive the most appropriate medication based on coverage and clinical needs. The system also helps reduce administrative burden by streamlining prior authorizations, saving time, and improving visibility into patient care. Physicians can manage all aspects of prescriptions in one place, including prescribing, refilling, tracking, and responding to patient needs more efficiently.

All medications under the HAFA program are dispensed through PhilRx, Harrow’s specialty pharmacy partner, with home delivery. Prescriptions are integrated directly through providers’ EMR systems, so patients automatically receive HAFA benefits—no copay cards, no extra steps, the company said.